June 13, 2011
SPCK, IFRS, RYUN, NHPR, MDCE PSMH
These Spotlights have made tremendous moves. As you can see, StockGuru brings you the very stocks you want on your radar, in your portfolio and to trade.
|StockGuru Spotlight Date||Spotlight Price||Symbol||High||Up As Much As||Market Cap|
|May 23, 2011||$ 0.25||AHNR||$ 0.43||72%||$13.21M|
|May 16, 2011||$ 0.43||PWON||$ 1.50||249%||$239.87M|
|May 11, 2011||$ 0.032||GNPG||$ 0.046||44%||$6.33M|
|May 11, 2011||$ 0.05||INVA||$ 0.065||30%||$3.67M|
|May 10, 2011||$ 0.52||BWMS||$ 0.65||25%||$30.13M|
|May 5, 2011||$ 0.87||TBIO||$ 1.67||92%||$78.88M|
Transgenomic, Inc. (OTCBB: TBIO) had good financial results reported on May 12, 2011, and had an exclusive acquisition on May 26. is a global biotechnology company advancing personalized medicine in cancer and inherited diseases through its proprietary molecular technologies and clinical and research services. The company has three complementary business divisions: Transgenomic Pharmacogenomic Services is a contract research laboratory that specializes in supporting all phases of pre-clinical and clinical trials for oncology drugs in development. Transgenomic Clinical Laboratories specializes in molecular diagnostics for cardiology, neurology, mitochondrial disorders, and oncology. Transgenomic Diagnostic Tools produces equipment, reagents, and other consumables that empower clinical and research application in molecular testing and cytogenetics. Transgenomic believes there is significant opportunity for continued growth across all three businesses by leveraging their synergistic capabilities, technologies, and expertise.
On May 26, 2011, the Company acquired an exclusive worldwide license to Montefiore Medical Center’s (Bronx, NY, US) patent application.
On May 12, 2011, the Company reported Q1 Financial Results:
- Net sales for the first quarter of 2011 were $7.5 million, an increase of 37 percent compared with $5.4 million for the same period in 2010. Gross profit was $4.2 million or 56 percent of net sales, compared with gross profit of $2.9 million or 53 percent of net sales for the same period in 2010.
- The increase in revenue is primarily due to our recent acquisition of the FAMILION family of genetic tests on December 29, 2010, as we operated this business the entire quarter.
These Companies continue to hit new highs. Check out the StockGuru Spotlight potential. While we know you can never catch the absolute high or the absolute low, these Companies represent the StockGuru Spotlight potential.
StockGuru brings you trading news you can use and meaningful trends:
Our StockGuru Spotlight Picks Are Published Before the Open Each Morning
StockGuru Spotlights are featured on our web site. We have an RSS feed and an exclusive twitter feed for StockGuru Spotlights. We also issue press releases on the StockGuru Spotlights; you can see proof positive our notice to you is truly an advanced notice. StockGuru is not not jumping on these after they move. Here is the link to BOOKMARK for Spotlights: http://www.stockguru.com/tag/spotlight
Don’t Miss Our on Spotlight Stocks! It is critical to catch these alerts in the morning prior to the market open. I have been asked several times recently how to get them.
IMPORTANT: Bookmark this link: http://www.stockguru.com/tag/spotlight Check This Link Every Morning for New Spotlight Stocks All of these are date and time stamped so you know what is current today. You can also just go to STOCKGURU.COM and look for the link in the top navigation for “StockGuru Spotlight.” You can also put the RSS link into your RSS reader, such as my favorite “Google Reader.”
There are countless programs that make it easy to get RSS feeds on your wireless phone as well. This is foolproof BUT ONLY IF YOU CHECK YOUR RSS FEED REGULARLY! RSS link on the site. We do not yet send out Spotlight Alerts by email, in an attempt to give your email box a break. Spotlights occur several times weekly, and are released ONLY when we see a valid reason. Occasionally, our Spotlights are compensated picks, but an editorial decision is made as to whether the situation qualifies as a market sensitive pick and we ALWAYS include a disclosure prominently if we include a company for which we have been compensated in either cash or shares.
StockGuru is in its Ninth Year!